AKBA - Akebia resubmits U.S. marketing application for kidney disease therapy
2023-09-28 08:51:12 ET
More on Akebia
- Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript
- Akebia: 'Hold' Through Regulatory And Financial Hurdles
- Akebia Therapeutics: Take Profits Before Second Quarter Report
- Akebia gains as Australia clears kidney disease therapy
- Akebia spikes as H.C. Wainwright upgrades on potential vadadustat approval
For further details see:
Akebia resubmits U.S. marketing application for kidney disease therapy